Preventing weight gain and increased waist circumference during the first two years after antipsychotic initiation in youth with first-episode psychosis

2016 ◽  
Vol 33 (S1) ◽  
pp. S112-S113 ◽  
Author(s):  
P. Ward ◽  
J. Curtis ◽  
S. Rosenbaum ◽  
A. Watkins ◽  
S. Teasdale ◽  
...  

BackgroundWe recently demonstrated that weight gain could be prevented in young people experiencing a first-episode of psychosis commencing treatment with antipsychotics. A 12-week, intensive lifestyle and life skills intervention – the Keeping the Body in Mind program, – was delivered by dedicated nursing, dietetic and exercise physiology clinicians, for new referrals with < one month of antipsychotic exposure. (Curtis et al., Early intervention in psychiatry, in press). At the conclusion of the intervention the 16 young people participating in the program experienced a mean weight gain of 1.8 kilograms, and a mean increase in waist circumference of 0.1 centimeters. The participants were followed up for two years after initial referral.MethodsDuring the two-year follow-up, participants had continuing access to an in house gym and weekly cooking groups, but without the same intensity of follow-up. Two year follow-up data were obtained from 11 participants form the original cohort.ResultsMean weight gain at two-year follow-up was 0.90 (SD 8.7) kilograms, and this difference was not statistically significant [t (10) = 0.3, NS]. Waist circumference decreased by 0.7 (SD 7.7) centimeters, which was not t statistically significant [t (10) = 0.3, NS]. Nine of the participants (82%) did not experience clinically significant weight gain two years after initiation of antipsychotic medication.ConclusionThis two-year follow-up data demonstrated that it is feasible to prevent weight gain in youth with first-episode psychosis over the first two years of treatment.Disclosure of interestThe authors have not supplied their declaration of competing interest.

2015 ◽  
Vol 169 (1-3) ◽  
pp. 458-463 ◽  
Author(s):  
Jaakko Keinänen ◽  
Outi Mantere ◽  
Tuula Kieseppä ◽  
Teemu Mäntylä ◽  
Minna Torniainen ◽  
...  

2010 ◽  
Vol 177 (3) ◽  
pp. 305-308 ◽  
Author(s):  
Jo Robinson ◽  
Meredith Harris ◽  
Sue Cotton ◽  
Ally Hughes ◽  
Philippe Conus ◽  
...  

2014 ◽  
Vol 159 (1) ◽  
pp. 70-75 ◽  
Author(s):  
Kally Yuen ◽  
Susy M. Harrigan ◽  
Andrew J. Mackinnon ◽  
Meredith G. Harris ◽  
Hok Pan Yuen ◽  
...  

2018 ◽  
Vol 44 (suppl_1) ◽  
pp. S226-S226
Author(s):  
David Fraguas ◽  
Sandra Recio ◽  
Covadonga M Diaz-Caneja ◽  
Maria A Blasco ◽  
Ana Carolina Moisés ◽  
...  

2015 ◽  
Vol 30 (1) ◽  
pp. 20-25 ◽  
Author(s):  
C. González-Blanch ◽  
J.F. Gleeson ◽  
S.M. Cotton ◽  
K. Crisp ◽  
P.D. McGorry ◽  
...  

AbstractCarers’ expressed emotion (EE) and patients’ cannabis misuse are two of the most robust predictors of psychotic relapse. We aimed to examine the temporal relationship between EE and cannabis misuse. Sixty-three key carers of young people with first-episode psychosis (FEP) were assessed at baseline and 7-month follow-up. EE was measured in carers using the Family Questionnaire (FQ) and cannabis misuse in patients using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Correlational and hierarchical logistic regression analyses were conducted to examine the temporal relationship between EE components (i.e. criticism and emotional over involvement) and cannabis misuse. Carers’ criticism at baseline significantly predicted cannabis misuse according to the ASSIST at 7-month follow-up. The association remained significant after controlling for baseline symptom severity and social functioning (B = 0.15, P = .02). Conversely, baseline cannabis misuse was not associated with carers’ criticism at 7-month follow-up. Patients in families with high criticism showed a tendency to increase cannabis misuse over time whereas the opposite trend was observed in those with carers with low criticism. A family environment characterized by high criticism may become a key risk factor for worsening cannabis misuse over time in young people with FEP. Further studies should investigate the potential mechanisms (e.g., patient's anxiety or perceived stress) through which criticism increases cannabis misuse in FEP.


2019 ◽  
Author(s):  
Sue Cotton ◽  
Michael Berk ◽  
Amity Watson ◽  
Stephen Wood ◽  
Kelly Allott ◽  
...  

Abstract Background First episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given at the early stages. Nonetheless, the efficacy of antipsychotic medications is suboptimal, particularly for negative and cognitive symptoms, and more efficacious and benign treatments are needed. Previous studies have shown the antioxidant amino acid N-acetyl cysteine (NAC) reduces negative symptoms and improves functioning in chronic schizophrenia and bipolar disorder. Research is scarce as to whether NAC is beneficial earlier in the course of illness. The primary aim of this study is to determine the efficacy of treatment with adjunctive NAC (2g/day for 26 weeks) compared with placebo to improve psychiatric symptoms in young people experiencing FEP. Secondary aims are to explore the neurobiological mechanisms underpinning NAC and how they relate to various clinical and functional outcomes at 26- and 52-week follow-up. Methods ENACT is a 26-week randomised controlled trial of adjunctive NAC versus placebo, with a 26-week non-treatment follow-up period, for FEP. We will be recruiting 162 young people aged 15-25 years who have recently presented to, and are being treated at, the Early Psychosis Prevention and Intervention Centre, Melbourne, Australia. The primary outcome is the Total Score on the Positive and Negative Syndrome Scale which will be administered at baseline, and weeks 4, 8, 12, 26 (primary endpoint), and 52 (end of study). Secondary outcomes include: symptomatology, functioning, quality of life, neurocognition, blood-derived measures of; inflammation, oxidative and nitrosative stress, and magnetic resonance spectroscopy measures of glutathione concentration. Discussion Targeted drug development for FEP to date has generally not involved the exploration of neuroprotective agents. This study has the potential to offer a new, safe, and efficacious treatment for people with FEP, leading to better treatment outcomes. Additionally, the neuroprotective dimension of this study may lead to a better long-term prognosis for people with FEP. It has the potential to uncover a novel treatment that targets the neurobiological mechanisms of FEP and, if successful, will be a major advance for psychiatry.


2014 ◽  
Vol 50 (2) ◽  
pp. 219-226 ◽  
Author(s):  
Wing Chung Chang ◽  
Emily S. M. Chen ◽  
Christy L. M. Hui ◽  
Sherry K. W. Chan ◽  
Edwin Ho Ming Lee ◽  
...  

2003 ◽  
Vol 60 (1) ◽  
pp. 156 ◽  
Author(s):  
U. Schall ◽  
S.A. Halpin ◽  
S.A. Hunt ◽  
J. Beckmann ◽  
B. Chenoweth ◽  
...  

2012 ◽  
Vol 46 (2) ◽  
pp. 100-108 ◽  
Author(s):  
Wing Chung Chang ◽  
Jennifer Y Tang ◽  
Christy L Hui ◽  
May M Lam ◽  
Sherry K Chan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document